Literature DB >> 32438491

Surgical Treatments of Hepatobiliary Cancers.

Ganesh Gunasekaran1, Yuki Bekki1, Vennis Lourdusamy2, Myron Schwartz1.   

Abstract

Hepatobiliary cancers which include hepatocellular carcinoma (HCC) and biliary tract cancers (i.e., cholangiocarcinoma and gallbladder carcinoma) are associated with significant morbidity and mortality based on the stage of the disease at presentation. With improved screening for hepatobiliary malignancies in patients with risk factors and with widespread use of laparoscopic cholecystectomy, hepatobiliary malignancies, including incidental diagnosis of gallbladder carcinoma, are on the rise. Definitive treatment of hepatobiliary malignancies include surgical resection, ablation, and liver transplantation. However, management of these cancers is challenging due to the complex hepatobiliary anatomy and the need for meticulous perioperative management especially in patients with advanced liver disease. The management and prognosis of hepatobiliary malignancies vary widely based on the stage of presentation, with surgical options providing the possibility of definitive cure in patients presenting with early-stage disease. Surgical resection for HCC results in good outcomes if performed in ideal candidates. For patients with early HCC who are not candidates for surgical resection, ablation and liver transplantation should be considered. Similarly, surgical resection is also the definitive treatment for biliary tract cancers, and liver transplantation can be curative in selected patients with perihilar cholangiocarcinoma after neoadjuvant chemoradiotherapy. The role of routine adjuvant chemotherapy and radiotherapy is not clearly established, but adjuvant therapies can offer better outcomes in patients with advanced disease at presentation. Outcomes of surgical management of hepatobiliary cancers seem to be improving. Given the complex decision-making process involved, multidisciplinary evaluation is essential to provide and coordinate the best treatments for these patients.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2020        PMID: 32438491     DOI: 10.1002/hep.31325

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  29 in total

1.  Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010-2018.

Authors:  Florian Hucke; Matthias Pinter; Miriam Hucke; Simona Bota; Dajana Bolf; Monika Hackl; Markus Peck-Radosavljevic
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

2.  Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma.

Authors:  Rui Li; Weiheng Zhao; Rui Liang; Chen Jin; Huihua Xiong
Journal:  Front Mol Biosci       Date:  2022-06-30

3.  An mALBI-Child-Pugh-based nomogram for predicting post-hepatectomy liver failure grade B-C in patients with huge hepatocellular carcinoma: a multi-institutional study.

Authors:  Ming-Hao Xu; Bin Xu; Chen-Hao Zhou; Zhong Xue; Zhao-Shuo Chen; Wen-Xin Xu; Cheng Huang; Xiao-Dong Zhu; Jian Zhou; Jia Fan; Hui-Chuan Sun; Ying-Hao Shen
Journal:  World J Surg Oncol       Date:  2022-06-16       Impact factor: 3.253

4.  Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles.

Authors:  Chenghua Song; Jia Zhang; Ruichao Wen; Qingshan Li; Jiaxuan Zhou; Zheng Wu; Yi Lv; Rongqian Wu
Journal:  Mater Today Bio       Date:  2022-07-06

5.  LukS-PV inhibits hepatocellular carcinoma cells migration by downregulating HDAC6 expression.

Authors:  Xuexue Xu; Pengsheng Ding; Lan Shi; Gang Wu; Xiaoling Ma
Journal:  BMC Cancer       Date:  2022-06-08       Impact factor: 4.638

6.  Prognostic significance of systemic immune-inflammation index-based nomogram for early stage hepatocellular carcinoma after radiofrequency ablation.

Authors:  Yujing Xin; Yi Yang; Ning Liu; Yi Chen; Yanan Wang; Xinyuan Zhang; Xiao Li; Xiang Zhou
Journal:  J Gastrointest Oncol       Date:  2021-04

Review 7.  From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis.

Authors:  Raphael Mohr; Burcin Özdirik; Joeri Lambrecht; Münevver Demir; Johannes Eschrich; Lukas Geisler; Teresa Hellberg; Sven H Loosen; Tom Luedde; Frank Tacke; Linda Hammerich; Christoph Roderburg
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

8.  Analysis of metastasis and survival between extrahepatic and intrahepatic cholangiocarcinoma: A large population-based study.

Authors:  Peng Liao; Li Cao; Hang Chen; Shui-Zi Pang
Journal:  Medicine (Baltimore)       Date:  2021-04-23       Impact factor: 1.817

9.  Hypoxia-Inducible Ubiquitin Specific Peptidase 13 Contributes to Tumor Growth and Metastasis via Enhancing the Toll-Like Receptor 4/Myeloid Differentiation Primary Response Gene 88/Nuclear Factor-κB Pathway in Hepatocellular Carcinoma.

Authors:  Shan Gao; Tianxiang Chen; Lijie Li; Xin Liu; Yang Liu; Junjun Zhao; Qiliang Lu; Zhi Zeng; Qiuran Xu; Dongsheng Huang; Kangsheng Tu
Journal:  Front Cell Dev Biol       Date:  2020-10-19

10.  A novel preoperative predictive model of 90-day mortality after liver resection for huge hepatocellular carcinoma.

Authors:  Yue Yin; Jian-Wen Cheng; Fei-Yu Chen; Xu-Xiao Chen; Xin Zhang; Ao Huang; De-Zhen Guo; Yu-Peng Wang; Ya Cao; Jia Fan; Jian Zhou; Xin-Rong Yang
Journal:  Ann Transl Med       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.